CTI Biopharma Corp reports results for the quarter ended in March - Earnings Summary

CTI Biopharma

07/05/2021 22:48

* CTI Biopharma Corp  CTIC.OQ  reported a quarterly adjusted
loss of 23 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 22 cents per share.
* Revenue was $0.00​​;  analysts expected $0.00.
* CTI Biopharma Corp's reported EPS for the quarter was a loss
of 23 cents​.
* The mean earnings estimate of analysts had fallen by
about 31.8% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* CTI Biopharma Corp shares had fallen by 23.7% this quarter and
lost 31.1% so far this year.
* The company reported a quarterly loss of $17.27 million.
* Wall Street's median 12-month price target for CTI Biopharma
Corp is $5.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 7 at 09:48 p.m. GMT. ​All
figures in US Dollars.​